Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Non-Current Liabilities (2016 - 2026)

Anika Therapeutics has reported Other Non-Current Liabilities over the past 17 years, most recently at $726000.0 for Q1 2026.

  • Quarterly Other Non-Current Liabilities fell 2.42% to $726000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $726000.0 through Mar 2026, down 2.42% year-over-year, with the annual reading at $701000.0 for FY2025, 9.2% down from the prior year.
  • Other Non-Current Liabilities was $726000.0 for Q1 2026 at Anika Therapeutics, up from $701000.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $806000.0 in Q3 2024 and troughed at $398000.0 in Q4 2022.
  • The 5-year median for Other Non-Current Liabilities is $587000.0 (2022), against an average of $577882.4.
  • Year-over-year, Other Non-Current Liabilities tumbled 96.53% in 2022 and then skyrocketed 101.5% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $398000.0 in 2022, then grew by 1.51% to $404000.0 in 2023, then skyrocketed by 91.09% to $772000.0 in 2024, then decreased by 9.2% to $701000.0 in 2025, then increased by 3.57% to $726000.0 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Other Non-Current Liabilities are $726000.0 (Q1 2026), $701000.0 (Q4 2025), and $761000.0 (Q3 2025).